Brokerages Set Theravance Biopharma, Inc. (NASDAQ:TBPH) PT at $21.33

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) have received an average recommendation of “Moderate Buy” from the eight analysts that are presently covering the firm, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and two have issued a strong buy rating on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $21.3333.

A number of equities analysts recently issued reports on TBPH shares. B. Riley Financial reaffirmed a “neutral” rating and issued a $14.00 price target (down from $28.00) on shares of Theravance Biopharma in a report on Wednesday, March 4th. BTIG Research restated a “buy” rating and set a $21.00 price objective on shares of Theravance Biopharma in a research report on Friday, March 20th. HC Wainwright upped their target price on shares of Theravance Biopharma from $20.00 to $27.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Zacks Research raised shares of Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a research report on Thursday, March 19th. Finally, Wall Street Zen upgraded shares of Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a research note on Sunday, March 29th.

Insider Activity at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 31,067 shares of Theravance Biopharma stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $13.96, for a total transaction of $433,695.32. Following the sale, the senior vice president owned 232,699 shares in the company, valued at approximately $3,248,478.04. The trade was a 11.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 6.90% of the company’s stock.

Institutional Trading of Theravance Biopharma

A number of large investors have recently made changes to their positions in the company. Quarry LP purchased a new stake in shares of Theravance Biopharma in the third quarter valued at about $26,000. Caitong International Asset Management Co. Ltd raised its holdings in Theravance Biopharma by 107.4% during the third quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 1,411 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in Theravance Biopharma by 26.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock valued at $46,000 after purchasing an additional 515 shares during the period. Tower Research Capital LLC TRC lifted its position in Theravance Biopharma by 18.5% in the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 781 shares during the period. Finally, CIBC Private Wealth Group LLC boosted its holdings in Theravance Biopharma by 20,269.6% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock valued at $68,000 after purchasing an additional 4,662 shares in the last quarter. 99.10% of the stock is owned by institutional investors and hedge funds.

Theravance Biopharma Price Performance

Theravance Biopharma stock opened at $16.02 on Tuesday. The stock has a market cap of $824.87 million, a PE ratio of 7.89 and a beta of 0.17. The stock’s fifty day moving average is $17.13 and its two-hundred day moving average is $16.94. Theravance Biopharma has a 1-year low of $7.90 and a 1-year high of $21.03.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.